If you're researching BPC-157, start with the question most marketing skips: is it even approved? The short version is no, and the longer version is genuinely in flux in 2026. Here's the plain-English picture.
The simple answer
BPC-157 has never been approved by the FDA as a drug for any use. It hasn't gone through the large human clinical trials that approval requires. So no one can honestly call it FDA-approved, and any product page implying otherwise is misrepresenting it.
How it ended up "under review"
In 2023, the FDA placed a group of peptides, BPC-157 among them, into a category that effectively blocked them from being compounded while the agency evaluated safety. That's what put BPC-157 in limbo: not approved, and for a time not compoundable either.
What's happening in 2026
The picture began shifting in 2026. The FDA scheduled its Pharmacy Compounding Advisory Committee to review seven peptides on July 23–24, 2026, and BPC-157 is one of them. That review will weigh whether it can be added to the list pharmacies may lawfully compound — but a scheduled review is not approval, and the accurate status today is "under evaluation." We track every development on our 2026 Updates page.
What this means if you're curious
"Under review" is not "available to buy and use." Until the status actually changes, BPC-157 isn't an approved consumer product, and the accurate, safe move is a conversation with a licensed provider rather than an online vendor.